CorMedix Inc. - 8-K Filing

FDA accepted for Priority Review a supplemental NDA seeking approval of REZZAYO® (rezafungin) for prophylaxis of invasive fungal diseases with PDUFA target action date in Q1 2027. (Items: 7.01 Regulation FD Disclosure On October 19, 2026, CorMedix, Inc, 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No)

SEC EDGAR · October 19, 2026, 12:00 UTC

Tickers: $CRMD

Read the full article at SEC EDGAR

More Regulatory news

Solana Co - 10-Q Filing SEC EDGAR · November 12, 2026, 13:42 UTC
Solana Co - 8-K Filing SEC EDGAR · November 12, 2026, 13:41 UTC
DeFi Development Corp. - 8-K Filing SEC EDGAR · November 12, 2026, 13:41 UTC
Stablecoin Development Corp - 8-K Filing SEC EDGAR · November 12, 2026, 13:40 UTC
BCP Investment Corp - 8-K Filing SEC EDGAR · November 12, 2026, 13:36 UTC
OneWater Marine Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:37 UTC
Moleculin Biotech, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:37 UTC
Investcorp Credit Management BDC, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:37 UTC
Presurance Holdings, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:35 UTC
Corteva, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:34 UTC